$49 per month*
Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic covers Johnson & Johnson’s Revenue Breakdown, split across Consumers, Medical Devices, and Pharmaceutical, reported on a quarterly basis from Q1 2016 onwards.
Johnson & Johnson generates revenue from the following segments:
|Segment||Q4 2019||Q4 2020||YoY Growth||Revenue Share Q4 2020|
(all figures in billions, except percentages)
Johnson & Johnson’s total revenue rose from $20.96 billion in Q4 2019 to $21.50 billion in Q4 2020, marking an increase of 2.57% on a year-on-year basis. During this period, the revenue growth was driven by higher sales of medicines like Stelara, Darzalex, Imbruvica, Opsumit, and Tremfya.
Johnson & Johnson’s Consumer segment offers a variety of products for oral care, baby care, skincare, and many other personal healthcare products. The company’s major brands include Clean & Clear, Neutrogena, Aveeno, Benadryl, Nicorette, Listerine, Stayfree, Carefree, Band-Aid, Neosporin, and many others. These products are used for the treatment of allergy, cough and cold, smoking cessation, and pain relief. Johnson & Johnson sells these products in different parts of the world through retail outlets, distributors, and e-commerce websites.
Johnson & Johnson’s revenue from the Consumer segment increased from $3.57 billion in Q4 2019 to $3.62 billion in Q4 2020, a growth of 1.40% on a year-on-year basis. In Q4 2020, the Consumer segment contributed 16.84% to the company’s total revenue.
Johnson & Johnson’s Medical Devices segment includes various types of devices used in Surgery, Interventional Solutions, Orthopaedics, and Vision Fields.
The company distributes these products to retailers and hospitals and is used by doctors, nurses, ophthalmologists, and physicians.
Johnson & Johnson’s revenue from the Medical Devices segment declined from $6.63 billion in Q4 2019 to $5.93 billion in Q4 2020, marking a decline of 10.55% on a year-on-year basis. During this period, the Medical Devices segment contributed 27.58% to Johnson & Johnson’s total revenue.
Johnson & Johnson’s Pharmaceutical segment focuses on Immunology, Pulmonary Hypertension, Neuroscience, Infectious Diseases, Cardiovascular and Metabolism, and Oncology. The company’s major brands in the Pharmaceutical segment includes:
Johnson & Johnson’s revenue from the Pharmaceutical segment rose from $10.76 billion in Q4 2019 to $11.95 billion in Q4 2020, a growth of 11.05% on a year-on-year basis. In Q4 2020, the Pharmaceutical segment contributed 55.58% to Johnson & Johnson’s total revenue.
Johnson & Johnson is an American multinational healthcare company. The company was founded by James Johnson, Edward Johnson, and Robert Johnson in 1886. Johnson & Johnson’s main office is located in New Brunswick, New Jersey, United States. Alex Gorsky is the current Chairman and CEO of the company. Johnson & Johnson employs more than 130,000 people in different parts of the world. The company’s products are available in most parts of the world. Johnson & Johnson’s manufacturing facilities are located in United States, Europe, Africa, Asia, and the Pacific.
Johnson & Johnson faces tough competition from Novartis, Merck, Roche, Boston Scientific, Abbott, Glaxo Smith Kline, Pfizer, and Medtronic. Over the years, Johnson & Johnson has acquired companies like Momenta Pharmaceuticals, Mitek Products, Janssen, 3-Dimensional Pharmaceuticals, Auris Health, Verb Surgical, Taris Biomedical, and many more. These acquisitions have helped the company in increasing its product portfolio and fight competition in the markets. Johnson & Johnson is listed on the NYSE and is traded under the stock code “JNJ”.
Did you like Johnson & Johnson’s Revenue Breakdown statistic?
Access thousands of more such key performance indicator data points, on listed companies, with Business Quant.
You can also get started for free.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.